Successful Desensitization Protocol in an Infant Following Anaphylaxis Secondary to Recombinant Factor VIIa

被引:2
|
作者
Ulusoy Severcan, Ezgi [1 ]
Cigerci Gunaydin, Nursen [2 ]
Hekimci Ozdemir, Hamiyet [3 ]
Gulen, Figen [4 ]
Kavakli, Kaan [5 ]
Tanac, Remziye [6 ]
Demir, Esen [6 ]
机构
[1] Hlth Sci Univ, Dr Sami Ulus Matern & Children Training & Res Hos, Dept Pediat Allergy & Immunol, Ankara, Turkey
[2] Namik Kemal Univ, Div Pediat Allergy & Immunol, Dept Pediat, Fac Med, TR-59100 Tekirdag, Turkey
[3] Ege Univ, Fac Med, Dept Pediat, Div Pediat Oncol & Hematol, Izmir, Turkey
[4] Ege Univ, Fac Med, Div Pediat Allergy & Immunol, Izmir, Turkey
[5] Ege Univ, Fac Med, Dept Pediat, Div Hematol, Izmir, Turkey
[6] Ege Univ, Fac Med, Pediat Allergy & Immunol, Izmir, Turkey
关键词
desensitization; drug allergy; factor VIIa; ACTIVATED FACTOR-VII; FACTOR-IX DEFICIENCY; HYPERSENSITIVITY REACTIONS; RAPID DESENSITIZATION; DRUG HYPERSENSITIVITY; SAFETY; CHEMOTHERAPY; INHIBITORS; DIAGNOSIS; ALLERGY;
D O I
10.1089/ped.2019.1130
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background:Recombinant factor VIIa (rFVIIa) is a highly purified recombinant protein. It is approved for the treatment and prevention of bleeding episodes associated with congenital factor VII deficiency, congenital hemophilia with inhibitors, and Glanzmann's thrombasthenia. The most commonly reported adverse events are thrombolytic in nature. In this report, we present a successful desensitization protocol administered to an infant with a history of anaphylaxis to rFVIIa. Case:A male infant with a history of gingival bleeding at the age of 6 months was diagnosed with factor VII deficiency with a factor VII level of 1%. His sister also had diagnosis of factor VII deficiency. Our patient was hospitalized at 10 months of age with generalized petechiae and bloody stools. Twenty minutes after administration of rFVIIa, he developed anaphylaxis that responded to epinephrine and supportive care. Subsequently he was evaluated at the allergy clinic, where a skin prick test with rFVIIa was negative. However, the intradermal skin test, applied with 1/1,000 (1 mu g/1 mL, 0.1 mL) dilution of rFVIIa, showed induration of 8 mm (positive reaction). Because there is no alternative treatment for factor VII deficiency, we developed a successful 13-step desensitization protocol with rFVIIa (NovoSeven(R)). Desensitization was performed an additional 2 times using the same protocol, one of which was for a head injury and the other for a swollen knee since the period between the doses was similar to 3 months. Conclusion:Allergic reactions, such as anaphylaxis can occur without prior exposure. This can be due to the high molecular weight and structural property of the biological agent. In this report, we present an effective desensitization protocol for an infant with a history of anaphylaxis to rFVIIa. Desensitization protocols in this age group should be carried out in a medical facility and with specialized staff and equipment prepared to care for anaphylaxis.
引用
下载
收藏
页码:159 / 162
页数:4
相关论文
共 50 条
  • [21] Successful use of recombinant factor VIIa for treatment of severe postpartum hemorrhage
    Hamaekers, Ankie E. W.
    van Mook, Walther N. K. A.
    Offermans, J. P. M.
    Marcus, Marco A. E.
    [J]. AMERICAN JOURNAL OF CRITICAL CARE, 2006, 15 (04) : 399 - 401
  • [22] Successful treatment of intractable hemothorax with recombinant factor VIIa in a nonhemophilic patient
    Wei, Yu-Feng
    Ho, Chao-Chi
    Lin, Ming-Tzer
    Yuan, Ang
    Yu, Chong-Jen
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2006, 105 (09) : 765 - 769
  • [23] Successful use of recombinant factor VIIa in a patient with acquired Glanzmann thrombasthenia
    Tuffigo, M.
    Lazaro, E.
    James, C.
    Subtil, C.
    Viallard, J. -F.
    Fiore, M.
    [J]. HAEMOPHILIA, 2015, 21 (01) : E116 - E118
  • [24] Prospective review of thrombosis complications following recombinant factor VIIa
    Alexander, K.
    Marques, M.
    [J]. TRANSFUSION, 2008, 48 (02) : 81A - 81A
  • [25] Severe congenital factor V deficiency: Successful management of bleedings by recombinant factor VIIa
    Borel-Derlon, A
    Gautier, P
    Le Querrec, A
    L'Hirondel, JL
    [J]. THROMBOSIS AND HAEMOSTASIS, 1999, : 341 - 341
  • [26] Unexpected Anaphylaxis After Completing a Desensitization Protocol to Oxaliplatin: Successful Adjuvant Use of Omalizumab
    Prieto-Garcia, A.
    Noguerado, B.
    Rojas, P.
    Torrado, I
    Rodriguez-Fernandez, A.
    Tornero, P.
    [J]. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2019, 29 (01) : 53 - 55
  • [27] PROTAMINE SULFATE ALLERGY: ANAPHYLAXIS DURING AN INTRADERMAL SKIN TEST AND A SUCCESSFUL DESENSITIZATION PROTOCOL
    Hronek, B.
    Wedner, H. J.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 111 (05) : A65 - A66
  • [28] Prophylactic recombinant factor VIIa administration to an infant with congenital systemic juvenile xanthogranuloma
    De Santiago, Jesus
    Martinez-Garcia, Ernesto
    Giron, Jorge
    Salcedo, Concepcion
    Perez-Gallardo, Antonio
    [J]. PEDIATRIC ANESTHESIA, 2006, 16 (09) : 974 - 976
  • [29] Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation
    Gielen-Wijffels, SEMJ
    van Mook, WNKA
    van der Geest, S
    Ramsay, G
    [J]. INTENSIVE CARE MEDICINE, 2004, 30 (06) : 1232 - 1234
  • [30] Successful use of recombinant factor VIIA (rFVIIa) in traumatic liver injuries in children
    Kulkami, R
    Daneshmand, A
    Guertin, SR
    Fath, JJ
    Atwal, M
    Melvin, J
    LaFrance, S
    [J]. PEDIATRIC RESEARCH, 2002, 51 (04) : 251A - 251A